Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000791 | 1.00 | SIRT2 (0.48) | SIRT2CTSSCTSKKLK5ALDH1A1 | |
| SCHEMBL2002586 | 0.89 | CTSS (0.50) | SIRT2CTSSCTSKALDH1A1MAPT | |
| SCHEMBL4066188 | 0.89 | CTSS (0.50) | SIRT2CTSSCTSKALDH1A1MAPT | |
| SCHEMBL16645014 | 0.87 | KLK5 (0.45) | CTSSCTSKKLK5ALDH1A1MAPT | |
| SCHEMBL8232460 | 0.87 | KLK5 (0.45) | CTSSCTSKKLK5ALDH1A1MAPT | |
| SCHEMBL4074909 | 0.87 | CTSS (0.46) | CTSSCTSKKLK5HDAC6HDAC1 | |
| SCHEMBL6560965 | 0.87 | CTSS (0.46) | CTSSCTSKKLK5HDAC6HDAC1 | |
| SCHEMBL23963101 | 0.86 | PPARG (0.44) | CTSSKLK5ALDH1A1HDAC6HDAC1 | |
| SCHEMBL20821189 | 0.86 | CTSS (0.47) | CTSSCTSKKLK5HDAC6HDAC1 | |
| SCHEMBL18082636 | 0.86 | TRPA1 (0.52) | CTSSCTSKKLK5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976346-B1 | PHOSPHOHISTIDINE AND PHOSPHOTYROSINE ANALOGUES | UNIV SHEFFIELD (GB) | 2017-02-22 | — | — | EP | disclosed |
| CN-104395297-B | Sulfonamide derivatives and pharmaceutical use thereof | AJINOMOTO CO.,INC. (JP) | 2016-05-04 | — | — | CN | disclosed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| CN-101495502-A | N-terminally modified GLP-1 receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | CN | disclosed |
| US-7534763-B2 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| EP-2021014-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2021354-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | disclosed |
| CN-101360736-A | L-alanine derivatives | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | disclosed |
| CN-101282991-A | N-terminally modified GLP-1 receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2008-10-08 | — | — | CN | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| EP-1883652-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007139589-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | SIRT2 501/4885CTSS 2684/4885CTSK 1960/4885 |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | GLP1R, GIPR, GRPR | SIRT2 813/4885CTSS 3491/4885CTSK 2690/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | SIRT2 539/4885CTSS 2843/4885CTSK 2190/4885 |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | SIRT2 813/4885CTSS 3491/4885CTSK 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.